Pixabay

Sep 12, 2023

Presenting Health Incubator Helsinki batch 4 companies:

AarogyaAI’s identifies and predicts antimicrobial resistance with AI-powered genomics

Antibiotic resistance is a growing threat globally. AarogyaAI aims to identify antibiotic resistance in patients and assist policymakers by predicting future antimicrobial resistance with their AI-powered genomics platform. The startup is one of the companies chosen for the Health Incubator Helsinki 2023 programme.

In 2018, roughly 23% of the world’s population was infected by the bacteria causing tuberculosis. To treat tuberculosis infection, patients need to undergo up to six months of antibiotic treatments with huge side effects — and because of antimicrobial resistance, it might not even work. But what if a doctor could choose the right combination of the 19 available antibiotics the first time, and save patients months of unnecessary, often debilitating treatment?

AaroyaAI founders Avlokita Tiwari and Praapti Jayaswal

AarogyaAI

AarogyaAI’s founders Praapti Jayaswal (left) and Avlokita Tiwari

Getting the right drugs to the right patients

This is the problem that India-based AarogyaAI set out to solve. Aarogya, meaning “good health” in Sanskrit, was founded in 2019 by Avlokita Tiwari and Praapti Jayaswal. With a PhD focused on tuberculosis studies (Jayaswal) and masters in bioinformatics with research in antimicrobial resistance (Tiwari), they realised they could predict drug resistance using artificial intelligence and DNA sequence information from the bacteria infecting patients.

“We list out the drug resistance of a particular pathogen so we can give a complete report to the clinician about which drug not to give the patient”, says founder and CTO Tiwari.

“Where our solution can make the most difference is in economically weak areas, so patients can get treated quickly and efficiently and their families don’t have to give up all of their savings for long treatments”, adds Nidhi Misra, Head of PR and communications at AarogyaAI.

Startup Fast Facts

Name: AarogyaAI

Tech in one sentence: AarogyaAI uses intelligent genomics and AI to combat antibiotic resistance in infectious diseases.

Product: AAICare: Rapid antimicrobial resistance diagnosis software

Target market launch: October 2023

Founded: 2019

Team size: 20

Funding raised (by 08/2023): 855,000 USD

COVID-19 as a model of infectious disease surveillance

When the company was founded in 2019, founders Tiwari and Jayaswal found that people didn’t immediately understand the usefulness of sequencing the DNA of infectious diseases. But then followed the COVID-19 pandemic and the massive effort in genomic surveillance of variant strains.

“People started to understand what we were talking about”, says Tiwari.

Besides getting the right drugs to the right patients, information on genetic variants associated with drug resistance are key for policies of the United Nations and World Health Organization:

“So they can have an idea of where diseases are spreading. That gives a lot of information about drug distribution, what to target next, and areas of development”, says Tiwari.

This information is also important for pharmaceutical companies: to know how to better design new drugs that get around antibiotic resistance.

The Health Incubator Helsinki team helps us to understand market needs and particularly the regulatory pathways.

Health Incubator Helsinki opening doors towards EU expansion

With the pathogen identification process from DNA samples validated and a clinical trial wrapping up at one of the biggest hospitals in India, what is in the future for AarogyaAI?

“At the moment we are in the middle of our next fundraising round”, says Tiwari.

“We are looking at a couple of commercial contracts and global expansion.”

When thinking about EU expansion, Finnish resident Tiwari immediately thought of the Finnish investment ecosystem’s open and receptive atmosphere.

“If we think of EU, Helsinki needs to be our base!” says Tiwari.

“That’s why Health Incubator Helsinki made sense. The incubator team is super supportive and helpful in understanding market needs, how to pitch, and particularly the regulatory pathways. When entering a new market as a foreign company, it is important to understand the local ecosystem and its requirements before going to market. Health Incubator Helsinki is actively helping us do that.”

If you’re interested in supporting AarogyaAI, joining one of their open positions or collaborating on a clinical study, get in contact with the information below!

AarogyaAI contact: Praapti Jayaswal, praapti(a)aarogya.ai

Text: Lea Urpa, Giuliano Didio

More news

Health Capital Helsinki

AarogyaAI’s identifies and predicts antimicrobial resistance with AI-powered genomics

Getting the right drugs to the right patients

Startup Fast Facts

COVID-19 as a model of infectious disease surveillance

Health Incubator Helsinki opening doors towards EU expansion

More news

EsaDres redefines wound care with tailored solutions

Ankerias is revolutionising chronic pain treatment with AI

HUS Helsinki University Hospital recognised in the list of World’s Best Smart Hospitals 2025

Health Capital Helsinki

Newsletter

AarogyaAI’s identifies and predicts antimicrobial resistance with AI-powered genomics

Getting the right drugs to the right patients

Startup Fast Facts

COVID-19 as a model of infectious disease surveillance

Health Incubator Helsinki opening doors towards EU expansion

Share this entry

More news

Health Capital Helsinki

Newsletter

Follow us